OBJECTIVE: The objective of the study was to determine whether eclampsia has a different circulating profile of angiogenic (placental growth factor [PlGF]) and antiangiogenic factors (soluble vascular endothelial growth factor receptor-1 [sVEGFR-1] and soluble endoglin [sEng]) from severe preeclampsia. STUDY DESIGN: This cross-sectional study included pregnant women in the following groups: (1) normal pregnancy (n = 40); (2) severe preeclampsia (n = 40); and (3) eclampsia (n = 20). Maternal serum PlGF, sVEGFR-1, and sEng concentrations were determined using an enzyme-linked immunosorbent assay. RESULTS: The study results included the following: (1) the median concentration of sVEGFR-1 and sEng was higher and of PlGF was lower in severe preeclampsia or eclampsia than in normal pregnancy (P < .001 for all); and (2) the median concentrations of these 3 analytes did not differ significantly between patients with severe preeclampsia and those with eclampsia. CONCLUSION: Eclampsia is associated with higher maternal circulating concentrations of sVEGFR-1 and sEng and lower concentrations of PlGF than normal pregnancy but with similar concentrations to severe preeclampsia. These findings suggest that eclampsia shares a common pathogenic pathway as severe preeclampsia. Published by Mosby, Inc.
OBJECTIVE: The objective of the study was to determine whether eclampsia has a different circulating profile of angiogenic (placental growth factor [PlGF]) and antiangiogenic factors (soluble vascular endothelial growth factor receptor-1 [sVEGFR-1] and soluble endoglin [sEng]) from severe preeclampsia. STUDY DESIGN: This cross-sectional study included pregnant women in the following groups: (1) normal pregnancy (n = 40); (2) severe preeclampsia (n = 40); and (3) eclampsia (n = 20). Maternal serum PlGF, sVEGFR-1, and sEng concentrations were determined using an enzyme-linked immunosorbent assay. RESULTS: The study results included the following: (1) the median concentration of sVEGFR-1 and sEng was higher and of PlGF was lower in severe preeclampsia or eclampsia than in normal pregnancy (P < .001 for all); and (2) the median concentrations of these 3 analytes did not differ significantly between patients with severe preeclampsia and those with eclampsia. CONCLUSION:Eclampsia is associated with higher maternal circulating concentrations of sVEGFR-1 and sEng and lower concentrations of PlGF than normal pregnancy but with similar concentrations to severe preeclampsia. These findings suggest that eclampsia shares a common pathogenic pathway as severe preeclampsia. Published by Mosby, Inc.
Authors: M J Kupferminc; Y Daniel; T Englender; A Baram; A Many; A J Jaffa; I Gull; J B Lessing Journal: Am J Reprod Immunol Date: 1997-10 Impact factor: 3.886
Authors: Mary A Vadnais; Sarosh Rana; Hayley S Quant; Saira Salahuddin; Laura E Dodge; Kee-Hak Lim; S Ananth Karumanchi; Michele R Hacker Journal: Pregnancy Hypertens Date: 2012-01-01 Impact factor: 2.899
Authors: Kathleen M Powis; Thomas F McElrath; Michael D Hughes; Anthony Ogwu; Sajini Souda; Saul A Datwyler; Erik von Widenfelt; Sikhulile Moyo; Marisa Nádas; Joseph Makhema; Esther Machakaire; Shahin Lockman; Max Essex; Roger L Shapiro Journal: J Acquir Immune Defic Syndr Date: 2013-04-15 Impact factor: 3.731